癌免疫療法の世界市場動向...市場調査レポートについてご紹介

【英文タイトル】Global Cancer Immunotherapy Market Outlook 2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Introduction to Cancer Immunotherapy

2. Classification of Cancer Immunotherapy
2.1 Specific Cancer Immunotherapy
2.2 Non-Specific Cancer Immunotherapy

3. Cancer Immunotherapy by Vaccines
3.1 Introduction
3.2 Mechanism of Vaccines in Cancer Immunotherapy
3.2.1 Idiotype Cancer Vaccine Mechanism
3.2.2 Cellular Cancer Vaccines Mechanism
3.2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
3.2.4 Peptide Cancer Vaccine Mechanism
3.2.5 Tumor Host Interaction Cancer Vaccine Mechanism

4. Cancer Immunotherapy by Monoclonal Antibodies
4.1 Introduction
4.2 Mechanism of Monoclonal Antibodies in Cancer Immunotherapy

5. Cancer Immunotherapy by Adoptive Cell Transfer
5.1 Introduction
5.2 Mechanism of Adoptive Cell Transfer Cancer Immunotherapy

6. Cancer Immunotherapy by Immune Checkpoint Inhibitors
6.1 Introduction
6.2 Mechanism of Immune Checkpoint Inhibitors in Cancer Immunotherapy

7. Cancer Immunotherapy by Immunomodulators
7.1 Introduction
7.2 Mechanism of Immunomodulators in Cancer Immunotherapy

8. Cancer Immunotherapy by Cytokines
8.1 Introduction
8.2 Mechanism of Cytokines Cancer Immunotherapy

9. Cancer Immunotherapy by Interleukins
9.1 Introduction
9.2 Mechanism of Interleukinsin Cancer Immunotherapy

10. Cancer Immunotherapy by Interferon
10.1 Introduction
10.2 Mechanism of Interferon Cancer Immunotherapy

11. Cancer Immunotherapy by GM-CSF
11.1 Introduction
11.2 Mechanism of GM-CSF Cancer Immunotherapy

12. Cancer Immunotherapy Market Overview
12.1 Current Market Scenario
12.2 Cancer Immunotherapy Pipeline Overview

13. Global Cancer Immunotherapy Market Dynamics
13.1 Favorable Market Parameters
13.2 Commercialization Challenges

14. Global Cancer Immunotherapy Market Future Prospects

15. Cancer Cell Therapies Clinical Pipeline by Company, Indication & Phase
15.1 Unknown
15.2 Research
15.3 Preclinical
15.4 Clinical
15.5 Phase-I
15.6 Phase-I/II
15.7 Phase-II
15.8 Phase-III
15.9 Preregistration

16. Marketed Cancer Cell Therapies Drugs Clinical Insight
16.1 Sipuleucel-T (Provenge®)
16.2 T-Lymphocyte Cell Therapy(Immuncell-LC®)

17. Cancer Cytokines Clinical Pipeline by Company, Indication & Phase
17.1 Unknown
17.2 Research
17.3 Preclinical
17.4 Clinical
17.5 Phase-I
17.6 Phase-I/II
17.7 Phase-II
17.8 Phase-III

18. Marketed Cancer Cytokines Drugs Clinical Insight
18.1 Aldesleukin (Proleukin®)
18.2 Denileukin Diftitox (ONTAK®)
18.3 Interferon Alpha (Multiferon®)
18.4 Interferon Alpha-2a (Roferon-A®)
18.5 Interferon Alpha-2a (Veldona®)
18.6 Interferon Alpha-2a Biosimilar(Inferon™/Inmutag™)
18.7 Interferon Alpha-2b(Intron® A)
18.8 Interferon Alpha-2b Biosimilar(Bioferon™)
18.9 Interferon Alpha-2b Biosimilar (Intalfa®)
18.10 Interferon Alpha-2b Biosimilar
18.11 Interferon-Alpha-n3 (Alferon N®)
18.12 Interferon-Beta-1b (Feron®)
18.13 Interferon-Gamma (Ogamma®)
18.14 Interleukin-2 Biosimilar (Ilcass)
18.15 Teceleukin (Imunace™)

19. Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase
19.1 Unknown
19.2 Research
19.3 Preclinical
19.4 Clinical
19.5 Phase-I
19.6 Phase-I/II
19.7 Phase-II
19.8 Phase-II/III
19.9 Phase-III
19.10 Preregistration
19.11 Registered

20. Marketed Cancer Immunomodulators Clinical Insight

21. Cancer Vaccine Clinical Pipeline By Company, Indication & Phase
21.1 Research
21.2 Preclinical
21.3 Clinical
21.4 Phase-I
21.5 Phase-I/II
21.6 Phase-II
21.7 Phase-II/III
21.8 Phase-III
21.9 Preregistration
21.10 Registered

22. Marketed Cancer Vaccines Clinical Insight
22.1 Bladder Cancer Vaccine (PACIS®)
22.2 Bladder Cancer Vaccine
22.3 BV NSCLC 001
22.4 Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®)
22.5 Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®)
22.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)
22.7 Melanoma Vaccine (MVax®)
22.8 Melanoma Vaccine (Melacine®)
22.9 Racotumomab (Vaxira®)
22.10 Sipuleucel-T (Provenge®)
22.11 Tertomotide (LucaVax)
22.12 Vitespen (Oncophage®)

23. Cancer Monoclonal Antibodies Clinical Pipeline by Company, Indication & Phase
23.1 Unknown
23.2 Research
23.3 Preclinical
23.4 Clinical
23.5 Phase-I
23.6 Phase-I/II
23.7 Phase-II
23.8 Phase-II/III
23.9 Phase-III
23.10 Preregistration
23.11 Registered

24. Marketed Cancer Monoclonal Antibodies Drugs Clinical Insight

25. Competitive Landscape
25.1 Abbvie
25.2 Advaxis
25.3 Altor BioScience
25.4 Amgen
25.5 Biogen Idec
25.6 Biogenomics
25.7 Celldex Therapeutics
25.8 Dendreon Corporation
25.9 Eli Lilly
25.10 Expression Genetics
25.11 Galena Biopharma
25.12 Genmab
25.13 Gilead Sciences
25.14 GlaxoSmithKline
25.15 ImmunoCellular Therapeutics
25.16 ImmunoGen
25.17 Inovio Pharmaceuticals
25.18 IRX Therapeutics
25.19 Merck
25.20 NeoStem Oncology
25.21 NewLink Genetics
25.22 Northwest Biotherapeutics
25.23 Novartis
25.24 Peregrine Pharmaceuticals
25.25 Pfizer
25.26 Philogen
25.27 Regulon
25.28 Roche
25.29 Seattle Genetics
25.30 ZymoGenetics


【レポート販売概要】

■ タイトル:癌免疫療法の世界市場動向
■ 英文:Global Cancer Immunotherapy Market Outlook 2020
■ 発行日:2015年6月
■ 調査会社:KuicK Research
■ 商品コード:KUIK506192
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。